



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

8-Bromo-cAMP

Cat. No.:	HY-12306A
CAS No.:	23583-48-4
Molecular Formula:	C ₁₀ H ₁₁ BrN ₅ O ₆ P
Molecular Weight:	408.1
Target:	PKA; Apoptosis
Pathway:	Stem Cell/Wnt; TGF-beta/Smad; Apoptosis
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

H₂O : 5.74 mg/mL (14.07 mM; ultrasonic and warming and adjust pH to 9 with 1 M NaOH and heat to 60°C)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.4504 mL	12.2519 mL	24.5038 mL
	5 mM		0.4901 mL	2.4504 mL	4.9008 mL
	10 mM		0.2450 mL	1.2252 mL	2.4504 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	8-Bromo-cAMP (8-Br-Camp), a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP has anti-proliferative and apoptotic effects against cancer cells ^{[1][2]} .
IC ₅₀ & Target	PKA ^[1]
In Vitro	8-Bromo-cAMP (0.1/0.5 mM) enhances the reprogramming efficiency of human neonatal foreskin fibroblast (HFF1) cells, and 0.1 mM of 8-Bromo-cAMP shows a synergistic effect with Valproic acid (HY-10585) (0.5 mM) ^[1] . 8-Bromo-cAMP (20 μM, 24 and 48 h) induces apoptosis in esophageal cancer cell line (Eca-109) ^[2] . 8-Bromo-cAMP (0.5 mM, 2 days) induces decidualization of human endometrial stromal cells ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	8-Bromo-cAMP (60 mg/kg/day, i.p., 7 days) reduces tumor in CT26 tumor mice ^[4] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	CT26 tumor mice ^[4]
Dosage:	60 mg/kg/day
Administration:	i.p., 7 days
Result:	Decreases amounts of primary CRC tumor nodules and liver metastases. Reduces vasculogenic mimicry (PAS-CD31 staining of colorectal and intestinal tumors). Inhibits cAMP and VEGF expression, increases expression of PKA in tumor tissues.

CUSTOMER VALIDATION

- J Hazard Mater. 2024 Jun 7;475:134854.
- Part Fibre Toxicol. 2022 Feb 17;19(1):13.
- Sci Total Environ. 2022 Oct 10;842:156854.
- Cell Mol Life Sci. 2022 Nov 13;79(12):589.
- Cell Oncol. 2023 Mar 20.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Wang HM, et al. Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. World J Gastroenterol. 2005 Nov 7;11(41):6538-42.
- [2]. Baek MO, et al. Differential regulation of mTORC1 and mTORC2 is critical for 8-Br-cAMP-induced decidualization. Exp Mol Med. 2018 Oct 30;50(10):1-11.
- [3]. Wang S, et al. Angiogenesis and vasculogenic mimicry are inhibited by 8-Br-cAMP through activation of the cAMP/PKA pathway in colorectal cancer. Onco Targets Ther. 2018 Jul 2;11:3765-3774
- [4]. Wang Y, et al. A cyclic AMP analog, 8-Br-cAMP, enhances the induction of pluripotency in human fibroblast cells. Stem Cell Rev. 2011 Jun;7(2):331-41.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA